首页 >
法规速递
-
Page: Evaluation of medicinal products indicated for treatment of bacterial infections - Scientific guideline-2024/2/9
2024-03-11查看详情 > -
Page: ICH Q14 Analytical procedure development - Scientific guideline-2024/1/26
2024-03-11查看详情 > -
Page: Maximum residue limit (MRL) evaluation for biological substances - Scientific guideline-2024/1/26
2024-03-11查看详情 > -
Page: Clinical evaluation of medicinal products intended for treatment of hepatitis B - Scientific guideline-2024/1/26
2024-02-05查看详情 > -
Page: Maximum residue limit (MRL) evaluation for biological substances - Scientific guideline-2024/1/26
2024-02-05查看详情 > -
Page: ICH Q14 Analytical procedure development - Scientific guideline-2024/1/26
2024-02-05查看详情 > -
Page: Product-specific bioequivalence guidance-2024/1/15
2024-02-05查看详情 > -
Document: ICH Q5A(R2) Guideline on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin - Step 5-2024/1/3
2024-02-05查看详情 > -
ICH E6 (R2) Good clinical practice - Scientific guideline-2023/12/22
2024-01-03查看详情 > -
ICH Q2(R2) Validation of analytical procedures - Scientific guideline-2023/12/22
2024-01-03查看详情 >